MEETING ABSTRACTS

Open Access

Conference Proceedings – 6th International Conference on Molecular Diagnostics and Biomarker Discovery (MDBD 2022): Building Resilience in Biomedical Research



Penang, Malaysia. 11-13 October 2022

Published: 21 December 2022

0-1

Tissue-based proteomics: insight into molecular mechanisms in cervical carcinogenesis

Gaayathri Kumarasamy¹, Mohd Nazri Ismail^{1, 2}, Sharifah Emilia Tuan Sharif³, Christopher Desire⁴, Parul Mittal⁴, Peter Hoffmann⁴ and Gurjeet Kaur¹

¹Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, 11800 Minden, Pulau Pinang, Malaysia; ²Analytical Biochemistry Research Centre (ABrC), Universiti Sains Malaysia, 11900 Bayan Lepas, Pulau Pinang, Malaysia; ³Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia; ⁴Clinical Health Sciences, University of South Australia, City West Campus, Adelaide, South Australia, 5000, Australia

Correspondence: Gurjeet Kaur (gurjeet@usm.my) *BMC Proceedings* 2022, **16(Suppl 7):**O-1

From The International Conference on Molecular Diagnostics & Biomarker Discovery 2022 (MDBD 2022) Penang, Malaysia. 11 – 13 October 2022

Background

Tissue-based proteomics is an evolving tool used in cancer research to characterize the pathophysiology of disease. However, the proteome alterations involved in cervical carcinogenesis are not extensively studied. This study aims to elucidate the differentially expressed proteins and offer insights into the cellular processes and pathways involved in the development of cervical cancer.

Methodology

The pathological regions of interest in the cervical squamous epithelium were micro-dissected from formalin-fixed paraffinembedded (FFPE) tissue sections of six normal cervix cases, five HPV-associated squamous intraepithelial lesion (SIL), and six squamous cell carcinomas (SCC). The samples were trypsin digestion and subjected to high throughput liquid chromatography-

electrospray ionization-tandem mass spectrometry (LC/ESI-MS/MS) and trapped ion mobility time-of-flight-mass spectrometry (tim-sTOF-MS), followed by quantification with MaxQuant and Perseus software. Bioinformatics analyses were carried out using DAVID, ConsensusPathDB, and STRING.

Results and Discussion

We identified a total of 3597 proteins with 589, 550, and 1570 proteins unique to the normal cervix, SIL, and SCC groups, respectively, while 332 proteins were similar across all three groups. The predominant protein found was histone. Interestingly, the quantification results showed an upward trend for the up-regulated proteins and a downward trend for the down-regulated proteins in the progression from normal to SIL and SCC. The main molecular function was the binding process, and the top biological processes were chromatin silencing for SIL compared to the normal cervix and nucleosome assembly for the SCC compared to SIL group. The key pathways involved were viral carcinogenesis and necroptosis, reflecting their role in cell proliferation, migration, and metastasis.

Conclusion

The identification of proteins and their associated pathways provides a deeper understanding of the underlying molecular mechanisms involved in HPV-associated cervical cancer.

Acknowledgement: The work was funded by the Fundamental Research Grant Scheme (FRGS/1/2019/SKK13/USM/01/1) from the Ministry of Education, Malaysia.

References

- [1] F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA. Cancer J. Clin. 68 (2018) 394–424.
- [2] W.S. Jr, M.A. Bacon, A. Bajaj, L.T. Chuang, Cervical cancer: a global health crisis. (2017) 1–9.
- [3] M. Vu, J. Yu, O.A. Awolude, L. Chuang, Cervical cancer worldwide, Curr. Probl. Cancer. 42 (2018) 457–465.



© The Author(s). 2022 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

during the analytical pipeline [3] that is important to identify challenges of systematic bias challenge in this study. The objective of this study was to evaluate the quality of NGS data sequence using FastQC in the early part of transcriptomic analysis pipelines of antiproliferative effects of dichloromethane CN fractions extracts on human breast cancer cell lines for biomarker discovery.

Methodology

Dichloromethane CN leaves extract with 50% inhibitory concentration (IC₅₀) value of 108µg/mL was exposed to the human breast cancer cells, MCF-7 for 72hrs chosen from a previous study. RNA was extracted from the treated and untreated cells for transcriptomic sequence, NGS technology using the Illumina HiSeq4000 platform. The sequencing output was the raw data that must be removed from the adapter sequences by the short read trimmed using FastQC (Babraham Bioinformatics, UK). This analysis uses the Linux operating system, Ubuntu 18.0v and the adapter was removed by a barcode tool, FlexbarFlexbarth its command line and script. All results were presented in multiQC which aggregated the results and generated a single HTML report with plots to visualize and compare various metrics between the samples involved.

Results and Discussion

The output of multiQC was filed from FastQC. In the summary report of FastQC status, important attention was made based on sequence quality and sequence length distribution. After RNA sequencing using the paired ends modules samples generated GC overall percentage of 54% and a length of 150bp showing no difference in GC composition and no biased library complexity, differences in amplification, or library specific causes. The sequence quality resulted in a pass or good result in the green area and more than 30 phred scores for all samples. As a result, the total overrepresented sequences found in each library make up more than 0.1% of the total that was passed and good quality which does not affect the biological consideration. Overall, the quality of RNA-seq data was high and the sequence quality was also good.

Conclusion

Multi QC report using FastQC is an advantageous tool because it is relatively quick to generate and provides a clear method for comparing samples to determine consistency and identify problematic samples. From this study, the multiQC report contains high quality clean data that was downstream in all future transcriptomic analyses for biomarker discovery in breast cancer research.

Acknowledgement: The work was funded by the Fundamental Research Grant Scheme (FRGS/203/CIPPT/6711340) from the Ministry of Higher Education, Malaysia and USM Brifging Grant (304/CIPPT/6316239) to PM Dr Hasni Arsad.

References

- Taemook Kim, et al. Octopus-toolkit: a workflow to automate mining of public epigenomic and transcriptomic next-generation sequencing data. Nucleic Acid Research. 2018, 46:9.
- [2] Guilherme de Sena Brandine and Andrew D.Smith. Falco: high-speed FastQC emulation for quality control of sequencing data. F1000Research. 2021, 8:1874.
- [3] Christoper M.Ward, et al. ngsReports; an R package for managing FastQC report and other NGS related log files.bioRxiv. 2018.

P-18

IGF-1 and IGFBP-1 expressions as the potential prognostic biomarkers in women with Endometrioid Endometrial Cancer (EEC)

Abdul Muzhill Hannaan Abdul Hafizz^{1, 2}, Reena Rahayu Md Zin¹, Nor Haslinda Abd Aziz², Muaatamarulain Mustangin¹, Nirmala Chandralega Kampan², Norfilza Mohd Mokthar³, Kah Teik Chew² and Mohamad Nasir Shafiee²

¹Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia; ²Department of Obstetrics and Gynaecology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia; ³Department of Physiology, Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia

Correspondence: Mohamad Nasir Shafiee (nasirshafiee@hotmail.com) BMC Proceedings 2022, 16(Suppl 7):P-18

From The International Conference on Molecular Diagnostics & Biomarker Discovery 2022 (MDBD 2022) Penang, Malaysia. 11 – 13 October 2022

Background

Insulin-like growth factor-1 (IGF-1) and the IGF binding protein 1 (IGFBP-1) expressions have been shown to play a vital role in cancer biology, including endometrioid endometrial cancer (EEC). We examined the prognostic value of these locally expressed biomarkers in endometrial biopsies and correlated them with clinicopathological data of EEC.

Methodology

mRNA expression of *IGF-1* and *IGFBP-1* in the endometrial biopsies were analysed in patients with EEC (n=25) and control (n=25) cases using quantitative polymerase chain reaction (qPCR) method. These data were then validated using immunohistochemistry (IHC) analysis and combined with EEC cases form a separate cohort (n=71) comprised of consecutive patients who underwent hysterectomy at UKMMC, between the year of 2014 to 2019. Overall survival was evaluated using the Kaplan-Meier method, with differences compared using the log- rank test. Independent relationships between these biomarkers and clinicopathological data were assessed using multivariate logistic regression models.

Results and Discussion

The IGF-1 and IGFBP-1 mRNA expressions were not significantly different between both groups, EEC vs. control. However, IGF-1 expression in IHC analysis was observed to be highly expressed in the EEC compared to the control group, while IGFBP-1 had a low expression in the EEC cases (P<0.05). IGF-1 was significantly associated with prognostic features of EEC (P<0.05), while no associations were found in the IGFBP-1 expression. In our sub-analysis, high IGF-1 and negative IGFBP-1 expression were significantly correlated with poor progression-free survival (PFS) in advanced stage of EEC (P<0.05). Univariate and multivariate analyses showed that IGF-1 served as a predictive biomarker in EEC survival. Therefore, we postulate the continuous high expression of local IGF-1 protein in EEC cells could lead to poor outcomes. Our findings support that the circulating estrogen and IGF-1 were independently associated with a higher risk of recurrence in patients with stage III and IV of EC (Merritt et al. 2021). We also propose that a shift in the local expression of IGFBP-1 and IGF-1 may serve as a biomarker for the prognosis of EEC development.

Conclusion

Local expression of IGF-1 and IGFBP-1 may serve as prognostic biomarkers for EEC.

Acknowledgement: The work was funded by the Dana Fundamental PPUKM (FF-2019-492) from Universiti Kebangsaan Malaysia.

Reference

[1] Merritt, M. A., Strickler, H. D., Hutson, A. D., Einstein, M. H., Rohan, T. E., Xue, X., Sherman, M. E., Brinton, L. A., Yu, H. & Miller, D. S. 2021. Sex Hormones, Insulin, and Insulin-Like Growth Factors in Recurrence of High-Stage Endometrial Cancer. Cancer Epidemiology and Prevention Biomarkers 30(4): 719-726

P-19

Pharmacological consequence of inhibiting MAPK p38 using Ralimetinib dimesylate on lipopolysaccharide-induced E-selectin and VCAM-1 expression in HUVEC

Dayang Erna-Zulaikha

Department of Paraclinical Sciences, Universiti Malaysia Sarawak, 94300, Sarawak, Malaysia

Correspondence: Dayang Erna-Zulaikha (ahdezulaikha@unimas.my) BMC Proceedings 2022, 16(Suppl 7):P-19

From The International Conference on Molecular Diagnostics & Biomarker Discovery 2022 (MDBD 2022) Penang, Malaysia. 11 – 13 October 2022

Background

Endothelial dysfunction plays a prominent role in the pathogenesis of sepsis and is associated with life-threatening organ dysfunction. Lipopolysaccharide (LPS), a Gram-negative bacterial component, is an important sepsis-associated mediator that induces the expression of adhesion molecules such as E-selectin and VCAM-1 upon its binding to dedicated pattern recognition receptors on endothelial cells (EC) [1]. Endothelial E-selectin and VCAM-1 expression promotes leukocyte adhesion, and high leukocyte infiltration in various organs is associated with a poor prognosis in sepsis patients. As the expression of E-selectin and VCAM-1 is partly driven by the

activation of the MAPK p38 signaling pathway [2], it is unknown whether Ralimetinib dimesylate (RM), a selective p38 MAPK inhibitor, can be used as a treatment to reduce E-selectin and VCAM-1 expression once LPS-driven activation of EC has started. RM treatment was previously shown to reduce TNF-a production in LPS-induced macrophages *in vitro* [3]. In this study, I investigated the pharmacological effect of RM treatment on E-selectin and VCAM-1 expression in LPS-stimulated HUVEC was investigated.

Methodology Ten μ M of RM was added into the HUVEC medium at 0.5, 1, 1.5, and 2 hours after HUVEC was exposed to 1 μ g/ml of LPS. After 2, 4, 5, and 6 hours of LPS exposure, the cells were trypsinized and subjected to flow cytometry analyses. The Mean Fluorescence Intensity (MFI) of E-selectin and VCAM-1- conjugated fluorochromes were determined in the treatment groups and statistically compared to LPS-stimulated HUVEC controls using one-way ANOVA and Bonferroni post-hoc test. Each group was represented by three biological replicates. The results were reported as mean + SD. Viability of HUVEC was monitored microscopically.

Results and Discussion

LPS induced the expression of E-selectin and VCAM-1 in HUVEC in a time-dependent manner. E-selectin and VCAM-1 were maximally expressed on HUVEC at 4 and 6 hours after LPS exposure, respectively. E-selectin expression was attenuated throughout the 6 hours' duration of LPS exposure upon post-LPS treatment with RM at 0.5, 1, 1.5, and 2 hours after LPS exposure. VCAM-1 expression was not affected upon post-LPS treatments with RM. These findings suggest that MAPK p38 to be an important signaling cascade mediating LPS-induced E-selectin expression and can be pharmacologically targeted to attenuate E-selectin, but not VCAM-1 expression.

Conclusion

RM can be used to pharmacologically target the p38 MAPK signaling pathway to attenuate the expression of E-selectin, but not VCAM-1, in LPS-activated EC. Follow-up *in vivo* study should be done to investigate the effect of RM on the expression of E-selectin and VCAM-1 in animal model of experimental sepsis.

References

- J. Moser et al. Intracellular RIG-I Signaling Regulates TLR4-Independent Endothelial Inflammatory Responses to Endotoxin. J. Immunol., 2016; 196: 4681–4601
- [2] E.-Z. Dayang et al. Identification of LPS-Activated Endothelial Subpopulations With Distinct Inflammatory Phenotypes and Regulatory Signaling Mechanisms. Front. Immunol., 2019; 10: 1–12.
- [3] Y. Yang et al. Functional Roles of p38 Mitogen-Activated Protein Kinase in Macrophage-Mediated Inflammatory Responses. Mediators Inflamm., 2014; 1–13.

P-20

AST, ALT, Bilirubin and AST/ALT Ratio Role; COVID-19 Patients

Nor Amirah Mohammad Nazri ¹, Wan Norlina Wan Azman¹, Norsyuhadah Musa¹, Tuan Salwani Tuan Ismail¹, Azian Harun², Najib Majdi Yaacob³, Sarina Sulong⁴, Sirajudeen K.N.S⁵, Mahaya Che Mat⁶ and Hani Ajrina Zulkeflee⁷

¹ Department of Chemical Pathology, School of Medical Sciences, Universiti Sains Malaysia (Health Campus) Kelantan, Malaysia; ² Department of Medical Microbiology and Parasitology, Universiti Sains Malaysia (Health Campus) Kelantan, Malaysia; ³ Unit of Biostatistic and Research Methodology, Universiti Sains Malaysia (Health Campus) Kelantan, Malaysia; ⁴ Human Genome Centre, Universiti Sains Malaysia (Health Campus) Kelantan, Malaysia; ⁵ Department of Basic Medical, Kuliyyah of Medicine, International Islamic University Malaysia, Kuantan Campus, Malaysia; ⁶ Department of Pathology, Hospital Raja Perempuan Zainab II, Kelantan, Malaysia; ⁷ Department of Medical Sciences II, Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia

Correspondence: Nor Amirah Mohammad Nazri

(ciknoramirah@gmail.com)

BMC Proceedings 2022, 16(Suppl 7):P-20

From The International Conference on Molecular Diagnostics & Biomarker Discovery 2022 (MDBD 2022) Penang, Malaysia. 11 – 13 October 2022

Background

Impaired liver function upon admission has been linked to the severity of COVID-19 infection, yet the data is debated [1]. Therefore, this retrospective study aimed to evaluate the liver function among COVID-19 patients during hospitalization and its association with the disease severity.

Methodology

Patients aged 18 to 80 years with positive COVID-19 at Hospital Raja Perempuan Zainab II (HRPZ II), Kota Bharu, Kelantan, with available AST, ALT, Bilirubin, and AST/ALT ratio data on admission, were retrospectively evaluated from March 2021 until March 2022. Disease severity was categorized based on the Annex 2e guidelines by Ministry of Health Malaysia, which further classified them into mild to moderate disease (Stage 1-3) and severe to critical illness (Stage 4-5). The AST, ALT, Bilirubin, and AST/ALT ratio levels on Day 1 admission were archived from the electronic medical record system and compared between the two groups. Statistical analysis was performed using SPSS version 27. This study was approved by (JEPeM-USM) with protocol code USM/JEPeM/21100691 and the Ministry of Health Malaysia NMRR-21-762-58458 (IIR).

Results and Discussion

The study involved a total of 168 COVID-19 patients with a mean (SD) age of 46.67(16.10) for mild to moderate and 56.66(12.41) for severe to critical. There was a significant age group for both groups (pvalue=0.002). During hospitalization, 16(14.41%) patients progressed to death from severe to critically ill patients. Upon admission, the median (IQR) of AST and ALT were significantly higher in the severe to critical group compared to the mild to moderate group, [AST; 39.0(49.0) and 24.0(14.0), ALT 38.0(43.0) and 21.0(18.0)], p<0.05. However, there were no significant differences between both groups for bilirubin level and AST/ALT ratio. Non-survivors had higher AST and ALT levels compared to survivors, with median (IQR) of [AST 98.0(88.0) and 32.0 (26.0), ALT of 67.5(90.0) and 28.0(31.0), (p<0.05). Similarly, there were no significant differences between nonsurvivors and survivors for bilirubin and AST/ALT ratio. Our study supports the idea that abnormal liver function at admission has been shown to be associated with the disease severity and mortality of COVID-19 infection. Therefore, there is a need to observe hepatobiliary sequelae in COVID-19 survivors as there are dynamic changes in liver function following hospital discharge.

Conclusion

Abnormal AST and ALT level at admission has been shown to be associated with the disease severity and mortality of COVID-19 infection. Further study needed to evaluate liver damage in COVID-19 post-discharge.

Acknowledgements: This study is funded by the Ministry of Higher Education Malaysia for the Fundamental Research Grant Scheme with project code: FRGS/1/2021/SKK06/USM/03/6 and External Agencies UTAS MAJU SDN BHD, 304.PPSP.6150238.U167.

Reference

[1] Liao X, Li D, Ma Z, Zhang L, Zheng B, Li Z, Li G, Liu L, Zhang Z. 12-Month Post-Discharge Liver Function Test Abnormalities Among Patients With COVID-19: A Single-Center Prospective Cohort Study. Frontiers in Cellular and Infection Microbiology. 2022:431.

P-21

MALDI-TOF mass spectrometry-based strategy in discovery reproducible *N*-glycans in human fibroblast

Salina Abdul Rahman, Affandi Omar, Nur Jannaim Muhamad and Julaina Abdul Jalil

Inborn Errors of Metabolism and Genetics Unit, Nutrition, Metabolism and Cardiovascular Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Bandar Setia Alam, 40170 Shah Alam, Selangor, Malaysia

Correspondence: Salina Abdul Rahman (sar@moh.gov.my) BMC Proceedings 2022, **16(Suppl 7):**P-21

From The International Conference on Molecular Diagnostics & Biomarker Discovery 2022 (MDBD 2022) Penang, Malaysia. 11 – 13 October 2022